On March 3, a batch of Pfizer vaccines against COVID-19 was delivered to ensure the availability of vaccination for Kazakhstanis. Over 500 thousand doses of Comirnaty Original/Omicron BA.4-5 vaccines arrived in Kazakhstan under the Agreement between the Ministry of Health of the Republic of Kazakhstan and the Ministry of Health of the Slovak Republic.
For the transfer of humanitarian aid to the country, the Slovak side was represented by the Ambassador Extraordinary and Plenipotentiary of the Slovak Republic to the Republic of Kazakhstan and the Kyrgyz Republic Robert Kirnag and Counselor of the Embassy of the Slovak Republic in the Republic of Kazakhstan and the Kyrgyz Republic Pavol Kovatsovsky. And the representatives of the Kazakh side were the Vice Minister of Foreign Affairs of the Republic of Kazakhstan Roman Vasilenko, the chief sanitary doctor of the city of Almaty Alpysbayuly Kasymkhan, the managing director-member of the Board of SK-Pharmacy LLP Artur Kazhibaev, the chief specialist of the Department of the Committee for Medical and Pharmaceutical Control in the city of Almaty Nurbol Kenzhebay and Saule Zhakypova, Advisor to the Representative Office of the Ministry of Foreign Affairs of the Republic of Kazakhstan in Almaty.
The arrived vaccine, after the completion of the sticker procedure, will be promptly sent to the regions of the country, according to the order of the CSEC of the MZRK. And in the coming days, citizens of the Republic of Kazakhstan will be available for vaccination against coronavirus infection.
The logistics of immunobiological preparations will be carried out by a single distributor in compliance with all GMP and GDP standards, as well as the "cold chain". In order to strictly follow the instructions for storing the vaccine and prevent negative consequences, measures were taken to prepare for the delivery and use of the vaccine.
Comirnaty Original/Omicron BA.4-5 is the trade name for an anti-covid vaccine intended for use in individuals 12 years of age and older who have received at least the initial course of covid vaccination.
The resulting redesigned vaccines provide broader protection against different variants of the virus and are therefore expected to help maintain optimal levels of immune protection against COVID-19 as the virus evolves.
The profile committee of the European Medicines Agency (EMA) has recommended a marketing authorization for a COVID-19 vaccine containing Omicron BA.4 and BA.5 sub-variants. This vaccine is an adapted version of the original Comirnaty vaccine (Pfizer/BioNTech). The purpose of vaccine adaptation is to provide better protection against circulating and ever-changing strains of the virus.
Recall that in Kazakhstan, the following vaccines were used for vaccination of the population: QazVac, Sputnik V, Hayat-Vax, СoronaVac, Sinopharm, Comirnaty.
Reference:
The Committee for Medicinal Products for Human Use (CHMP) is the committee of the European Medicines Agency (EMA) responsible for human medicines.
The CHMP also evaluates nationally authorized medicines submitted to the EMA for their harmonized position in the EU. In addition, the CHMP and its working groups contribute to drug development and drug regulation.
Pfizer Inc. is an American multinational company, one of the largest pharmaceutical companies in the world. The company produced the most popular drug in the world, Lipitor; This drug is used to lower blood cholesterol levels and was sold for $125 billion between 1997 and 2012.
The vaccine is transported according to the “cold chain” principle – at each stage, strict maintenance of the temperature regime is ensured. At the same time, each level has its own responsible organization.
Transportation of vaccines takes place in 4 stages:
1. From the manufacturer to the hubs of the Single Distributor;
2. From the hubs of the Single Distributor to the warehouses of the regional health departments;
3. From warehouses of regional health departments to medical organizations;
4. Storage in medical organizations before use.
.png)
.jpeg)